KRYS Krystal Biotech, Inc.

QT69

Latest market price

302.32

+6.42+2.17%

Overview Short InterestFilings

KRYSQT69Krystal Biotech, Inc.·NASDAQ

Overview Short InterestFilings

302.32+2.17%

Filing

Up 2.2% — Filed an 8-K material-event report (2026-11-02) — details in the filing.

Medium confidence

Loading chart...

Signal & projected range

Earnings big beat — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

SYRE+3.46%$98.81 CYTK+2.32%$63.47 PTGX+2.80%$143.27 TWST+6.47%$137.38 CAI+4.66%$33.59 IBRX+4.97%$8.35 ARWR+1.28%$60.33 TGTX+1.86%$61.06

Snapshot

Index	—	P/E	37.08	EPS (ttm)	7.98	Insider Own	11.98%	Shs Outstand	29.60M	Perf Week	-5.66%

Market Cap	8.76B	Forward P/E	33.41	EPS next Y	8.86	Insider Trans	-3.57%	Shs Float	23.62M	Perf Month	-8.19%

Enterprise Value	7.92B	PEG	0.71	EPS next Q	—			Short Float	12.43%	Perf Quarter	-8.89%

Income	241.00M	P/S	19.91	EPS this Y	8.55%			Short Ratio	8.03	Perf Half Y	3.12%

Sales	440.00M	P/B	6.44	EPS next Y	20.89%	ROA	16.09%	Short Interest	2.94M	Perf YTD	20.02%

Book/sh	45.91	P/C	10.35	EPS next 5Y	51.91%	ROE	19.34%	52W High	382.54 -20.97%	Perf Year	56.49%

Cash/sh	28.58	P/FCF	34.08	EPS past 3/5Y	—	ROIC	14.39%	52W Low	184.02 64.29%	Perf 3Y	150.74%

Dividend Est.	—	EV/EBITDA	35.83	Sales past 3/5Y	—	Gross Margin	93.34%	Volatility	4.39% 3.55%	Perf 5Y	448.47%

Dividend TTM	—	EV/Sales	18.00	EPS Y/Y TTM	62.20%	Oper. Margin	44.93%	ATR (14)	12.98	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	7.96	Sales Y/Y TTM	22.56%	Profit Margin	54.82%	RSI (14)	34.81	Recom	2.00

Dividend Gr. 3/5Y	—	Current Ratio	8.32	EPS Q/Q	-22.93%	SMA20	-8.23%	Beta	0.66	Target Price	395.20

Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	23.96%	SMA50	-12.05%	Rel Volume	4.48	Prev Close	295.90

Employees	295	LT Debt/Eq	0.01	Earnings	Feb 16	SMA200	-4.12%	Avg Volume	268.74K	Price	302.32

IPO Date	Sep 20, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	14.53% —	Net Debt/EBITDA	-3.80	Volume	1,203,468	Change	2.17%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-24-26	Resumed	Goldman Sachs	Buy	$327 → $441
Aug-14-26	Initiated	RBC Capital	Outperform	$400
Jul-13-26	Reiterated	Jefferies	Buy	$399 → $474
Jun-16-26	Reiterated	HC Wainwright & Co.	Buy	$310 → $361
May-05-26	Reiterated	Evercore ISI Group	Outperform	$206 → $300
Feb-18-26	Reiterated	Chardan Capital	Buy	$216 → $323
Feb-17-26	Reiterated	Jefferies	Buy	$371
Jan-09-26	Reiterated	HC Wainwright & Co.	Buy	$310
Jan-06-26	Upgrade	Citigroup	Neutral → Buy
Oct-17-25	Reiterated	Guggenheim	Buy	$189 → $224

Latest News· Times ET

Nov-02-26

Nov-02-2601:43PM

Krystal Biotech Analyst Says Stock Weakness 'Overblown'benzinga.com

01:28PM

Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call Transcriptseekingalpha.com

12:20PM

Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimateszacks.com

12:16PM

Nasdaq Rallies as Tech Stocks Recover From Friday's Selloffschaeffersresearch.com

11:14AM

Krystal Biotech Q3 Earnings Call Highlightsmarketbeat.com

07:00AM

Krystal Biotech Announces Third Quarter 2026 Financial and Operating Resultsglobenewswire.com

Oct-28-26

Oct-28-2604:22AM

Has The Story Under Krystal Biotech Stock Run Out?Yahoo

Oct-26-26

Oct-26-2611:01AM

Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out forzacks.com

Oct-22-26

Oct-22-2608:00AM

Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026Yahoo

Oct-16-26

Oct-16-2612:20PM

KRYS Reports Positive Early Data for KB113 in Gorlin Syndromezacks.com

Oct-15-26

Oct-15-2610:06AM

Krystal Biotech Reports KB113 Lesion Regression in Gorlin Syndrome Pilot Study as FDA Discussions BeginYahoo

07:00AM

Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndromeglobenewswire.com

Oct-13-26

Oct-13-2607:24AM

2,490 Shares in Krystal Biotech, Inc. $KRYS Purchased by Terra Nova Asset Management LLCdefenseworld.net

Oct-10-26

Oct-10-2606:33AM

Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Valueseekingalpha.com

05:08AM

Krystal Biotech: Vyjuvek's Success Is Becoming Its Growth Problem (Downgrade)SeekingAlpha

Company

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	440	389	291	51	—	—	—	—	—
Cost of Goods Sold Incl. D&A	29	29	20	3	—	—	—	—	—
Gross Profit	411	360	270	48	—	—	—	—	—
Selling, General and Administrative Excl. Other	160	147	114	98	—	—	—	—	—
Research and Development	59	58	54	46	—	—	—	—	—
Other Operating Expense	-6	-6	37	13	—	—	—	—	—
Operating Income	197	161	66	-110	—	—	—	—	—
Interest Expense	0	0	0	0	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	30	28	30	123	—	—	—	—	—
Net Income Before Taxes	226	189	95	13	—	—	—	—	—
Income Taxes	-14	-15	6	2	—	—	—	—	—
Consolidated Net Income	241	205	89	11	—	—	—	—	—
Net Income From Continuing Operations	241	205	89	11	—	—	—	—	—
Net Income	241	205	89	11	—	—	—	—	—
EPS (Recurring)	8.27	7.08	3.12	0.40	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	8.27	7.08	3.12	0.40	—	—	—	—	—
EPS (Diluted)	7.98	6.84	3.00	0.39	—	—	—	—	—
EBITDA	221	196	110	-92	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	37.89	36.04	52.22	318.10	—	—	—	—	—
Price To Sales Ratio	20.61	18.38	15.61	65.68	—	—	—	—	—
Gross Margin	93.41	92.54	92.78	94.12	—	—	—	—	—
Operating Margin	44.77	41.39	22.68	-215.69	—	—	—	—	—
Net Margin	54.77	52.70	30.58	21.57	—	—	—	—	—
Shares Outstanding	30	29	29	27	—	—	—	—	—
Market Capitalization	9,070	7,150	4,543	3,350	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Krishnan Suma	President, R&D	Sep 04 '26	Sale	359.32	25,000	8,982,986	1,302,145	Sep 04
Krishnan Krish S	President and CEO	Sep 04 '26	Sale	359.32	25,000	8,983,082	1,347,543	Sep 04
ROSSI DINO A	Director	Aug 14 '26	Sale	329.12	25,000	8,227,953	50,000	Aug 14
Thomas John Charles	EVP, General Counsel	Jun 25 '26	Option Exercise	179.25	1,000	179,250	1,000	Jun 26
Thomas John Charles	EVP, General Counsel	Jun 25 '26	Sale	347.27	1,000	347,270	0	Jun 26
Krishnan Suma	President, R&D	Jun 04 '26	Sale	308.11	25,000	7,702,826	1,378,155	Jun 05
Krishnan Krish S	President and CEO	Jun 04 '26	Sale	308.12	25,000	7,702,983	1,450,253	Jun 05
Thomas John Charles	EVP, General Counsel	May 26 '26	Sale	302.03	642	193,903	0	May 27
Krishnan Suma	President, R&D	Mar 04 '26	Sale	263.21	25,000	6,580,269	1,403,155	Mar 06
Krishnan Krish S	President and CEO	Mar 04 '26	Sale	263.17	25,000	6,579,164	1,475,253	Mar 06
ROMANO KATHRYN	Chief Accounting Officer	Mar 02 '26	Sale	267.60	750	200,700	22,366	Mar 03
ROMANO KATHRYN	Chief Accounting Officer	Feb 27 '26	Option Exercise	0.00	8,050	0	26,068	Mar 03
Krishnan Suma	President, R&D	Feb 27 '26	Option Exercise	0.00	67,225	0	1,509,075	Mar 03
Krishnan Krish S	President and CEO	Feb 27 '26	Option Exercise	0.00	67,225	0	1,509,075	Mar 03
JANNEY DANIEL	Director	Feb 27 '26	Sale	275.59	11,803	3,252,824	73,293	Mar 03

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.